Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus
about
Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancerAn Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate CancerGonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysisIn search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonist degarelix on human prostate cell growthIntegrative review on the non-invasive management of lower urinary tract symptoms in men following treatments for pelvic malignancies.A prospective, observational grouped analysis to evaluate the effect of triptorelin on lower urinary tract symptoms in patients with advanced prostate cancer.Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis.A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancerInternational prostate symptom score (IPSS) change and changing factor in intensity-modulated radiotherapy combined with androgen deprivation therapy for prostate cancer.Relationship between prostate volume changes and treatment duration of neoadjuvant androgen deprivation during intensity-modulated radiation therapy for Japanese patients with prostate cancerPredictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression.Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer.Degarelix: a review of its use in patients with prostate cancer.Triptorelin for the relief of lower urinary tract symptoms in men with advanced prostate cancer: results of a prospective, observational, grouped-analysis study.Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.Degarelix Versus Goserelin Plus Bicalutamide in the Short-Term Relief of Lower Urinary Tract Symptoms in Prostate Cancer Patients: Results of a Pooled Analysis.A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer.Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Clinical evaluation of tamsulosin in the relief of lower urinary tract symptoms in advanced prostate cancer patients.Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer.Androgen deprivation therapy improves pneumoperitoneum time during laparoscopic radical prostatectomy in Japanese patients with enlarged prostates.Therapeutic outcomes of the LHRH antagonists.Impact of Androgen Deprivation Therapy on Volume Reduction and Lower Urinary Tract Symptoms in Patients with Prostate Cancer.
P2860
Q26739738-FF1A7807-F069-4987-B363-3E3A0412B91BQ26744431-098DA51A-66CC-4BC2-AE61-E7A472AA4EF8Q26777150-287C9739-A14D-4C25-837C-522DBFFBCE93Q28545022-CDFD9C70-C1B8-4009-B9BF-BC45F68E8A44Q30373008-1FD5A5AD-59BE-4A47-BF85-48649B58EE06Q35797395-8680CE3A-C38D-4F10-94A6-BC456ACEE1A4Q36070721-163E5A92-A35B-47DD-9C3E-EF58503903F0Q36120758-A136FF50-11F9-442A-97D9-FCF6573311E7Q36332644-373429BD-E358-4D7E-BABA-64A945BFD01EQ37198359-4F01CA1E-12B5-4C76-B9FC-973D8A8C8DCCQ37424419-5D8EC432-8ECA-4491-8FC1-8C90C4ADFDACQ38193002-6FD279E6-F29C-4B84-B116-27EF3666BF06Q38206404-68A5C787-4ABC-4289-9B16-E1F78F153D96Q38658856-A556A1F9-C5CE-4A7B-8F17-F7F76402092EQ38798811-199D11A5-EE18-4259-B034-A395A632E052Q38844498-DF175FB6-DBDC-4358-97AA-714113845994Q38892158-377C1627-550F-4F83-8249-6DF14773F626Q39036192-DFB52194-FE75-4065-A47F-02E23A3ACB53Q39157031-C74F9D5A-B051-4A40-8A0E-9B11C0E8A9ABQ39247489-42E3057A-1F3A-4ED0-9766-D65D9812F6D2Q40106293-3D4DD674-0F66-4F7C-80D4-BCAB09F90300Q43857472-B1A2078F-158D-44AC-A984-37B0076D1055Q47859553-804B55C8-6E40-4CA9-ABF8-C26B7C3A0772Q48724046-1E8D8FE0-8CF1-4E0C-BA4C-B1C79CCA1B6E
P2860
Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Neoadjuvant androgen deprivati ...... rity trial of degarelix versus
@ast
Neoadjuvant androgen deprivati ...... rity trial of degarelix versus
@en
Neoadjuvant androgen deprivati ...... rity trial of degarelix versus
@nl
type
label
Neoadjuvant androgen deprivati ...... rity trial of degarelix versus
@ast
Neoadjuvant androgen deprivati ...... rity trial of degarelix versus
@en
Neoadjuvant androgen deprivati ...... rity trial of degarelix versus
@nl
prefLabel
Neoadjuvant androgen deprivati ...... rity trial of degarelix versus
@ast
Neoadjuvant androgen deprivati ...... rity trial of degarelix versus
@en
Neoadjuvant androgen deprivati ...... rity trial of degarelix versus
@nl
P2093
P1433
P1476
Neoadjuvant androgen deprivati ...... rity trial of degarelix versus
@en
P2093
E van der Meulen
P B F Bergqvist
X Maldonado Pijoan
P304
P356
10.1016/J.CLON.2012.09.010
P577
2012-12-17T00:00:00Z